Sánchez-Seco Victoria Galán, Casanova Peño Ignacio, Arroyo González Rafael
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España.
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España.
Med Clin (Barc). 2014 Dec;143 Suppl 3:30-4. doi: 10.1016/S0025-7753(15)30007-5.
Until the mid 1990s, with the appearance of interferon beta and glatiramer acetate, there was no treatment for multiple sclerosis (MS). However, due to their moderate therapeutic potential in some patients, a broad search was continued to find new and more effective treatment strategies, largely concentrated on monoclonal antibodies (MOAB). Natalizumab, the first MOAB for the treatment of MS, was approved at the end of 2004, representing a major advance in the field of neuroimmunology. Today, there is broad experience with natalizumab and other MOAB (alemtuzumab, daclizumab, rituximab, ocrelizumab, ofatumumab and anti-lingo-1) that are pending commercialization or are under phase II or III of development with promising results. The present review analyzes the efficacy and safety results of all these drugs.
直到20世纪90年代中期，随着β干扰素和醋酸格拉替雷的出现，多发性硬化症（MS）才有了治疗方法。然而，由于它们在一些患者中的治疗潜力有限，人们继续广泛寻找新的、更有效的治疗策略，主要集中在单克隆抗体（MOAB）上。那他珠单抗是首个用于治疗MS的MOAB，于2004年底获批，代表了神经免疫学领域的一项重大进展。如今，对于那他珠单抗和其他正在等待商业化或处于II期或III期开发且结果令人鼓舞的MOAB（阿仑单抗、达利珠单抗、利妥昔单抗、奥瑞珠单抗、奥法木单抗和抗Lingo-1）已有广泛经验。本综述分析了所有这些药物的疗效和安全性结果。
